Insider · CIK 0001682638
Emily Fairbairn
director
Files at MOVE (Movano Inc.), INAB (IN8BIO, INC.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 22, 2025 | INAB IN8BIO, INC. | AGrant or award Common Stockindirect: See footnote | +724,637 | $1.38 | $1000k | 724,637 | Dec 23, 2025 |
| Nov 3, 2025 | MOVE Movano Inc. | DDisposition to issuer Common Stock | -12,442 | $0.00 | $0 | 2,690 | Nov 10, 2025 |
| Nov 3, 2025 | MOVE Movano Inc. | AGrant or award Stock option (right to buy)derivative | +55,250 | $0.00 | $0 | 55,250 | Nov 10, 2025 |
| Oct 3, 2025 | MOVE Movano Inc. | AGrant or award Common Stock | +31,028 | $0.00 | $0 | 151,315 | Oct 8, 2025 |
| Jul 3, 2025 | MOVE Movano Inc. | AGrant or award Common Stock | +27,985 | $0.00 | $0 | 120,287 | Jul 3, 2025 |
| May 9, 2025 | MOVE Movano Inc. | AGrant or award Common Stock | +65,407 | $0.00 | $0 | 92,302 | May 13, 2025 |
| May 8, 2025 | INAB IN8BIO, INC. | AGrant or award Stock Option (right to buy)derivative | +63,150 | $0.00 | $0 | 63,150 | May 12, 2025 |
| Jan 2, 2025 | MOVE Movano Inc. | AGrant or award Stock Options (Right to Buy)derivative | +10,333 | $0.00 | $0 | 10,333 | Jan 6, 2025 |
| Dec 19, 2024 | INAB IN8BIO, INC. | AGrant or award Stock Option (right to buy)derivative | +31,559 | $0.00 | $0 | 31,559 | Dec 23, 2024 |
| Oct 9, 2024 | MOVE Movano Inc. | AGrant or award Stock option (right to buy)derivative10b5-1 | +130,000 | $0.00 | $0 | 130,000 | Oct 11, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.